Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
JNK is a stress-activated protein kinase that modulates pathways implicated in a variety of disease states. JNK-interacting protein-1 (JIP1) is a scaffolding protein that enhances JNK signaling by creating a proximity effect between JNK and upstream kinases. A minimal peptide region derived from JIP1 is able to inhibit JNK activity both in vitro and in cell. We report here a series of small molecules JIP1 mimics that function as substrate competitive inhibitors of JNK. One such compound, BI-78D3, dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell . In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes. Our findings open the way for the development of protein kinase inhibitors targeting substrate specific docking sites, rather than the highly conserved ATP binding sites. In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo , BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To our knowledge, these observations represent the first understanding of how JIP1 achieves such high affinity interactions compared to other known D-motif proteins, which can be used to direct structure based design efforts targeting the peptide-binding site (Stebbins et al., 2008).”
From Structural Mechanisms of Allostery and Autoinhibition in JNK Family Kinases (2012) · cites this paper as Stebbins et al., 2008
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · cited 6×
“1 (The Cambridge Crystallographic Data Centre) (28, 29) and analyzed with Sybyl.”
MethodInfluentialDérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Self-citationEldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., & Mee, R. P. (1997) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1007996124545 · Cited by 1,686 · cited 5×
“1 (The Cambridge Crystallographic Data Centre) (28, 29) and analyzed with Sybyl.”
MethodInfluentialSignal transduction by the c-Jun N-terminal kinase (JNK) — from inflammation to development
Ip, Y. T., & Davis, R. J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80143-9 · Cited by 1,547
Whitmarsh, A. J., & Davis, R. J. (1996) · Journal of Molecular Medicine · doi:10.1007/s001090050063 · Cited by 1,543
Selective interaction of JNK protein kinase isoforms with transcription factors.
Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Dérijard, B., & Davis, R. J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00636.x · Cited by 1,338 · cited 2×
“Although JNK1 and JNK2 are ubiquitous, JNK3 is principally present in the brain, cardiac muscle, and testis (4, 5).”
BackgroundA Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway
Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., Greenberg, M. E., Sawyers, C. L., & Davis, R. J. (1997) · Science · doi:10.1126/science.277.5326.693 · Cited by 675 · cited 2×
“The mechanism of JNK1 inhibition by pepJIP1 is mainly because of the competition of pepJIP1 with the D-domains of substrates or upstream kinases (15, 18).”
BackgroundA Mammalian Scaffold Complex That Selectively Mediates MAP Kinase Activation
Whitmarsh, A. J., Cavanagh, J., Tournier, C., Yasuda, J., & Davis, R. J. (1998) · Science · doi:10.1126/science.281.5383.1671 · Cited by 652 · cited 1×
“JNK-interacting protein-1 (JIP1) is a scaffolding protein that enhances JNK signaling by creating a proximity effect between JNK and upstream kinases (13).”
BackgroundKallunki, T., Su, B., Tsigelny, I., Sluss, H. K., Dérijard, B., Moore, G., Davis, R., & Karin, M. (1994) · Genes & Development · doi:10.1101/gad.8.24.2996 · Cited by 642
Self-citationTargeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585 · cited 1×
“Because these pathways are related to the pathogenesis of several diseases, including diabetes, cancer, atherosclerosis, stroke, and Alzheimer’s and Parkinson’s diseases, JNKs represent valuable targets in the development of new therapies (10).”
BackgroundCell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571
Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
Leppä, S., & Bohmann, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203173 · Cited by 522
c-Jun Can Recruit JNK to Phosphorylate Dimerization Partners via Specific Docking Interactions
Kallunki, T., Deng, T., Hibi, M., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81999-6 · Cited by 491 · cited 1×
“JNKs bind to scaffold proteins and substrates containing a D-domain, consensus sequence of which is R/KXXXXLXL (11, 12).”
BackgroundSelf-citationRegulation and function of the JNK subgroup of MAP kinases
Minden, A., & Karin, M. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00018-8 · Cited by 484
Self-citationPossible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide
Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T.-A., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y., & Hori, M. (2004) · Nature Medicine · doi:10.1038/nm1111 · Cited by 337 · cited 1×
“Recent in vivo data, generated in studies focusing on a cell-permeable JIP1 peptide consisting in pepJIP1 fused with the cell permeable HIV-TAT peptide, shows that its administration in both genetically and dietary mice models of insulin resistance and type 2 diabetes restores normoglycemia without causing hypoglycemi…”
BackgroundIntracellular targeting of polymer-bound drugs for cancer chemotherapy
NORI, A., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.006 · Cited by 303
Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1
Yang, S.-H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1740 · Cited by 299 · cited 1×
“JNKs bind to scaffold proteins and substrates containing a D-domain, consensus sequence of which is R/KXXXXLXL (11, 12).”
BackgroundIKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα
Maeda, S., Chang, L., Li, Z.-W., Luo, J.-L., Leffert, H., & Karin, M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00301-7 · Cited by 286
Self-citationStructural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125
Heo, Y., Kim, S., Seo, C. I., Kim, Y. K., Sung, B., Lee, H. S., Lee, J. I., Park, S., Kim, J. H., Hwang, K. Y., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600212 · Cited by 275 · cited 5×
“In addition, an extensive network of hydrogen bonding interactions is predicted between the triazole, nitro group, and thiazole of BI-78D3 with JNK1 R127, an interaction that has been demonstrated as critical for pepJIP1 binding to JNK1 (17).”
BackgroundResultInfluentialKyriakis, J. M., & Avruch, J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44910-6 · Cited by 260
Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity
Barr, R. K., Kendrick, T. S., & Bogoyevitch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107565200 · Cited by 211 · cited 3×
“The minimal region of JIP1, consisting of a single D-domain, has been identified as a JNK inhibitor (14, 16).”
BackgroundWang, Y., Singh, R., Lefkowitch, J. H., Rigoli, R. M., & Czaja, M. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512953200 · Cited by 207 · cited 1×
“The link between ConA-induced liver failure, TNF receptor signaling, and JNK function has been established by studies employing JNK1 / and JNK2 / mice (23, 24).”
JNK: a new therapeutic target for diabetes
Bennett, B. L., Satoh, Y., & Lewis, A. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00068-7 · Cited by 167
Developmental expression in the mouse nervous system of the p493F12 SAP kinase
Martin, J. H., Mohit, A. A., & Miller, C. A. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00181-q · Cited by 150 · cited 1×
“Although JNK1 and JNK2 are ubiquitous, JNK3 is principally present in the brain, cardiac muscle, and testis (4, 5).”
BackgroundHo, D. T., Bardwell, A. J., Abdollahi, M., & Bardwell, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304229200 · Cited by 108 · cited 1×
“The mechanism of JNK1 inhibition by pepJIP1 is mainly because of the competition of pepJIP1 with the D-domains of substrates or upstream kinases (15, 18).”
BackgroundOxidative Stress and the JNK Pathway are Involved in the Development of Type 1 and Type 2 Diabetes
Kaneto, H., Matsuoka, T.-A., Katakami, N., Kawamori, D., Miyatsuka, T., Yoshiuchi, K., Yasuda, T., Sakamoto, K., Yamasaki, Y., & Matsuhisa, M. (2007) · Current Molecular Medicine · doi:10.2174/156652407782564408 · Cited by 104
Texture mapping: A new tool for molecular graphics
Teschner, M., Henn, C., Vollhardt, H., Reiling, S., & Brickmann, J. (1994) · Journal of Molecular Graphics · doi:10.1016/0263-7855(94)80074-x · Cited by 75 · cited 1×
“Molecular surfaces were generated with MOLCAD (30).”
Development of Paramagnetic Probes for Molecular Recognition Studies in Protein Kinases
Vázquez, J., De, S. K., Chen, L., Riel-Mehan, M. M., Emdadi, A., Cellitti, J. F., Stebbins, J. L., Rega, M. F., & Pellecchia, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800068w · Cited by 40 · cited 1×
“To confirm the predicted binding mode of BI-78D3, we used a recently developed chemical probe (21) that, by anchoring in the ATP binding site, brings a paramagnetic spin label into proximity of the JIP binding site of JNK (Fig.”
MethodSelf-citationOxidative stress and the JNK pathway as a potential therapeutic target for diabetes
Kaneto, H., Kawamori, D., Nakatani, Y., Gorogawa, S., & Matsuoka, T. (2004) · Drug News & Perspectives · doi:10.1358/dnp.2004.17.7.863704 · Cited by 36
High-throughput cellular assays for regulated posttranslational modifications
Robers, M. B., Horton, R. A., Bercher, M. R., Vogel, K. W., & Machleidt, T. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.09.012 · Cited by 31 · cited 2×
“In an attempt to profile the properties of BI-78D3 in the context of a complex cellular milieu, we used the cell-based LanthaScreenTM kinase assay (22).”
BackgroundMethodSelf-citation
Research works printed but not linked: 1
- R. S Pearlman CONCORD, Distributed by Tripos (St. Louis). (1998).
Cited by
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586
Seki, E., Brenner, D. A., & Karin, M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.004 · Cited by 487
Self-citationTanti, J.-F., & Jager, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.07.004 · Cited by 430
Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
“These interactions were, for example, successfully exploited for development of inhibitors of JNK signalling (Stebbins et al., 2008; Chen et al., 2009), though no allosteric p38 MAPK inhibitors that would interrupt the binding with any of its substrates have been reported up to date.”
BackgroundDiscovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
“…phosphorylation of c-Jun using the measurement of time-resolved fluorescence resonance energy transfer (TR-FRET) between a stably expressed GFPc-Jun (1–79) fusion protein and a terbium-labeled anti pSer73 c-Jun antibody as readout (Robers et al., 2008; Carlson et al., 2009; Stebbins et al., 2008).”
Self-citation
Metadata
- Authors
- Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, L.-H., Cellitti, J. F., Riel-Mehan, M., Emdadi, A., Solinas, G., Karin, M., & Pellecchia, M.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Invitrogen Corporation, Invitrogen Discovery Services, 501 Charmany Drive, Madison, WI 53719; and
- *Infectious and Inflammatory Disease Center, Cancer Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037;
- University of California San Diego (US)
- Corresponding author
- Pellecchia, Maurizio
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-10-28
- Volume
- 105
- Issue
- 43
- Pages
- 16809-16813
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2567907
- OpenAlex
- W2007832743
- Cited by
- 186
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 14 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 6 · 2015: 13 · 2014: 8 · 2013: 7 · 2012: 23
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R24DK080263, R21DK073274)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- JNK, protein kinase inhibitors, c-Jun N-terminal kinase, type 2 diabetes, insulin sensitivity
- MeSH terms
- Animals, Binding, Competitive, Diabetes Mellitus, Experimental, Dioxanes, Insulin Resistance, Liver Diseases, Phosphorylation, Protein Binding, Thiazoles, Signal Transduction, Molecular Mimicry, Protein Kinase Inhibitors, JNK Mitogen-Activated Protein Kinases, Adaptor Proteins, Signal Transducing, Mice, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.